Literature DB >> 18460567

Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk.

Kaisa K Ivaska1, Janaka Lenora, Paul Gerdhem, Kristina Akesson, H Kalervo Väänänen, Karl J Obrant.   

Abstract

CONTEXT: One of the important challenges in the management of osteoporosis is to identify women who are at high risk of developing osteoporosis and fragility fractures.
OBJECTIVE: Our objective was to evaluate whether assessment of bone metabolism at multiple occasions can identify women with the highest risk for bone loss.
DESIGN: The Malmö Osteoporosis Prospective Risk Assessment study is an ongoing longitudinal study. Participants have been evaluated at baseline and after 1, 3, and 5 yr.
SETTING: We conducted a population-based study. PARTICIPANTS: Participants included 1044 women, all 75 yr old at baseline. MAIN OUTCOME MEASURES: Seven bone turnover markers were assessed at baseline and at 1, 3, and 5 yr (n = 573). The 5-yr change in areal bone mineral density (aBMD) was also determined.
RESULTS: Baseline markers correlated weakly to change in total body aBMD. The associations were more pronounced when the average of the baseline and 1-yr measurements was used (standardized regression coefficients -0.12 to -0.23, P < 0.01). Adding the 3-yr and 5-yr measurement further strengthened the correlation (regression coefficients up to -0.30, P < 0.001). Women with constantly high turnover lost significantly more bone at total body assessment (-2.6%) than women with intermediate (-1.6%) or low turnover (-0.2%, P for trend < 0.001). They also had a greater decrease in hip BMD (-8.3, -6.0, and -5.1%, respectively, P = 0.010). Results were similar also in the subgroup of women with osteopenia.
CONCLUSIONS: Our results suggest that serial assessment of bone turnover improves the identification of women with the highest rate of bone loss and osteoporosis risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460567     DOI: 10.1210/jc.2007-1508

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Bone turnover markers are correlated with quantitative ultrasound of the calcaneus: 5-year longitudinal data.

Authors:  J Lenora; P Gerdhem; K J Obrant; K K Ivaska
Journal:  Osteoporos Int       Date:  2008-10-23       Impact factor: 4.507

2.  Should serial assessment of bone turnover markers be included in fracture risk calculation in elderly women?

Authors:  Samuel D Vasikaran
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-11-18

3.  Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women.

Authors:  Maria Swanberg; Fiona McGuigan; Kaisa K Ivaska; Paul Gerdhem; Ulf H Lerner; Richard Bucala; George Kuchel; Anne Kenny; Kristina Akesson
Journal:  Bone       Date:  2010-05-12       Impact factor: 4.398

Review 4.  Bone markers in osteoporosis.

Authors:  Patrick Garnero
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

5.  Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study.

Authors:  E A Marques; V Gudnason; T Lang; G Sigurdsson; S Sigurdsson; T Aspelund; K Siggeirsdottir; L Launer; G Eiriksdottir; T B Harris
Journal:  Osteoporos Int       Date:  2016-06-24       Impact factor: 4.507

6.  The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Authors:  E Cavalier; P Bergmann; O Bruyère; P Delanaye; A Durnez; J-P Devogelaer; S L Ferrari; E Gielen; S Goemaere; J-M Kaufman; A Nzeusseu Toukap; J-Y Reginster; A-F Rousseau; S Rozenberg; A J Scheen; J-J Body
Journal:  Osteoporos Int       Date:  2016-03-30       Impact factor: 4.507

7.  Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial.

Authors:  J Nahas-Neto; L M Cangussu; C L Orsatti; F N Bueloni-Dias; P F Poloni; E B Schmitt; E A P Nahas
Journal:  Osteoporos Int       Date:  2018-02-15       Impact factor: 4.507

8.  Teriparatide and denosumab combination therapy and skeletal metabolism.

Authors:  L Idolazzi; M Rossini; O Viapiana; V Braga; A Fassio; C Benini; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-06-01       Impact factor: 4.507

9.  Biochemical markers in the follow-up of the osteoporotic patients.

Authors:  Alessandro Terreni; Paola Pezzati
Journal:  Clin Cases Miner Bone Metab       Date:  2012-09-30

10.  The gut microbiome is associated with bone turnover markers in postmenopausal women.

Authors:  Lin Chen; Shuai Yan; Ming Yang; Fudong Yu; Jingjing Wang; Xiaoxin Wang; Huanbai Xu; Jianxia Shi; Ling Pan; Yuexi Zeng; Siyu Li; Li Li; Li You; Yongde Peng
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.